Trial vaccine for clinical treatment of ovarian cancer Centers of America

Chicago, IL (Vocus) 30 May 2008

Cancer Treatment Centers of America (CCTA), a leading provider of innovative anti-cancer therapies for patients with complex and advanced disease, has begun accepting patients for the trial of a vaccine against ovarian cancer clinics. Phase I / II, recently reviewed and approved by the U.S. Food and Drug Administration (FDA), will evaluate the safety and effectiveness of individual therapies for ovarian cancer vaccine to a maximum of 42 patients with chemotherapy-resistant advanced ovarian cancer.

The study will be conducted exclusively at CTCA at Midwestern Regional Medical Center in suburban Chicago. Join CTCA, patients with stage III or IV ovarian cancer who have tumor progression despite at least one but not more than two chemotherapy regimens. The participants in the clinical trial must first directly from surgical intervention at CTCA at Midwestern Regional Medical Center and localized chemotherapy into the abdominal cavity (intraperitoneal chemotherapy), infused a standard of cancer treatment available to many patients, CTCA. Patients are eligible for the study vaccine against cancer of the ovary, where it is clear that tumor cells are harvested enough debulked tumor to create a vaccine against ovarian cancer and the vaccine has passed rigid quality control.

CTCA, Inc., a vaccine against ovarian tumor cells with custom-made by each patient were surgically removed to create CTCA. These cells will be amended in AVAX laboratories and will be developed to produce an immune response against cancer of the ovaries to treat the patient.

“The systematic use of a vaccine for the patient’s immune system to combat their own tumors following localized, high-dose chemotherapy struggle not yet been attempted before,” said Donald Braun, Ph.D., CTCA vice president for clinical research. Sybilann Brown and Mr. Williams, a gynecologist-oncologist and surgeon at CTCA collaboration with Dr. David Berd, Chief Medical Officer of AVAX, will serve as investigators.

“CTCA offers a powerful combination of traditional and innovative therapies by a team of cancer specialists who work with each patient to determine the desired combination of therapies against cancer, fight, Dr. Williams.” Ovarian cancer is a complex disease that is often resistant to chemotherapy, radiation therapy and surgery. CTCA offer our patients the opportunity to participate in another landmark step in the fight against ovarian cancer. “

ovarian cancer is considered the eighth most common cancer in women, and is the fifth leading cause of cancer death in women. It is estimated that there are 21 650 new cases of ovarian cancer in the United States in 2008 and 15 520 deaths from cancer. Ovarian cancer affects about one in 69 women after the National Alliance of ovarian cancer.

“We are thrilled, received FDA approval to begin this important clinical study and the opportunity it gives us will work with CTCA,” stated Dr. Berd AVAX. “Obviously, better treatment options for ovarian cancer needs and we hope that the vaccine eventually his place as a relatively nontoxic alternative treatment for these patients.”

More information about the vaccine trial is ovarian cancer, ovarian cancer and treatment will be found on CancerCenter.com. The patients in the clinical study is interested, a CTCA Oncology Information Specialist at

cancer treatment center of America:

founded in 1988, is Cancer Treatment Centers of America (CCTA) is a network of hospitals and cancer treatment community oncology programs in Illinois, Oklahoma, Pennsylvania and Washington – is to a site Future of Arizona is expected to open in spring 2009. CTCA provides a comprehensive treatment model, the patient is the center that integrates fully conventional, state-of-the-art medical treatments with scientific support complementary therapies such as nutrition, naturopathy, psychological counseling, physical therapy and spiritual support to meet specific, whole-person needs of cancer patients and complex diseases at an advanced stage. CTCA encourages patients and their families participate in treatment decisions through its Patient Empowerment Model MedicineSM. go for more information about cancer Centers of America to cancercenter.com.

Technologies, Inc.:

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The company is in research, clinical development and commercialization of biological products and therapies for cancer. In addition, the company provides contract manufacturing of biological products for other pharmaceutical and biotechnology companies.

###

clear = “all”
Treatment of ovarian cancer